Author: Rahman, Sayeeda; Montero, Maria Teresa Villagomez; Rowe, Kherie; Kirton, Rita; Kunik, Frank
Title: Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence Cord-id: 7vm9cp4g Document date: 2021_5_3
ID: 7vm9cp4g
Snippet: INTRODUCTION: The COVID-19 pandemic has created a public health crisis, infected millions of people, and caused a significant number of deaths. SARS-CoV-2 transmits from person to person through several routes, mainly via respiratory droplets, which makes it difficult to contain its spread into the community. Here, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of COVID-19. AREAS COVERED: Direct person-to-person respiratory transmission
Document: INTRODUCTION: The COVID-19 pandemic has created a public health crisis, infected millions of people, and caused a significant number of deaths. SARS-CoV-2 transmits from person to person through several routes, mainly via respiratory droplets, which makes it difficult to contain its spread into the community. Here, we provide an overview of the epidemiology, pathogenesis, clinical presentation, diagnosis, and treatment of COVID-19. AREAS COVERED: Direct person-to-person respiratory transmission has rapidly amplified the spread of coronavirus. In the absence of any clinically proven treatment options, the current clinical management of COVID-19 includes symptom management, infection prevention and control measures, optimized supportive care, and intensive care support in severe or critical illness. Developing an effective vaccine is now a leading research priority. Some vaccines have already been approved by the regulatory authorities for the prevention of COVID-19. EXPERT OPINION: General prevention and protection measures regarding the containment and management of the second or third waves are necessary to minimize the risk of infection. Until now, four vaccines reported variable efficacies of between 62–95%, and two of them (Pfizer/BioNTech and Moderna) received FDA emergency use authorization. Equitable access and effective distribution of these vaccines in all countries will save millions of lives.
Search related documents:
Co phrase search for related documents- abbott sars and accurate reliable: 1
- abbott sars and active infection: 1, 2
- abbott sars and acute kidney injury: 1
- abbott sars and acute phase: 1
- abbott sars and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60
- abbott sars and live virus: 1, 2, 3
- abbott sars and low number: 1
- abbott sars and low sensitivity: 1, 2, 3, 4
- abbott sars assay and active infection: 1
- abbott sars assay and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- abbott sars assay and live virus: 1, 2
- abbott sars assay and low number: 1
- abbott sars assay and low sensitivity: 1
Co phrase search for related documents, hyperlinks ordered by date